Compass Therapeutics Inc. (CMPX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $5.78
• Market Cap: $1.05B
• EPS: $-0.45
• 52-Week High: $6.88
• 52-Week Low: $1.33

Market Sentiment

Compass Therapeutics Inc. currently has a Bearish sentiment score of -0.17.

About Compass Therapeutics Inc.

Compass Therapeutics, Inc. is a Boston-based clinical-stage biopharmaceutical firm specializing in the development of innovative antibody-based therapies for cancer and other serious diseases. The company is focused on advancing its proprietary drug candidates through rigorous clinical trials, leveraging a state-of-the-art technology platform to create highly targeted treatments that aim to improve patient outcomes. With a pipeline dedicated to transforming the oncology landscape, Compass rep...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Compass Therapeutics Inc. and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CMPX pay dividends?

Compass Therapeutics Inc. (CMPX) does not currently pay a regular dividend.

What is CMPX's market cap?

Compass Therapeutics Inc. (CMPX) has a market capitalization of $1.05B with a current stock price of $5.78.